Latest metronidazole Stories
Results Reveal Rosacea's Emotional and Social Impact on Patients, Prompting Beauty Expert Charla Krupp and Expert Dermatologist, Dr.
- Up to $50 Million Potential Milestones plus Double Digit Royalties on Future Sales - - Company to Host Conference Call at 11:00 a.m. ET Today - EMERYVILLE, Calif., March 25 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc.
Resent studies reported that aspirin inhibited the growth of H. pylori in a dose-dependent manner and significantly affected the activity of virulence factors of H. pylori.
FORT WORTH, Texas, Feb. 3 /PRNewswire/ -- Galderma Laboratories, L.P. today announced that the U.S.
SAN ANTONIO, Feb. 3 /PRNewswire/ -- BioComp Pharma, Inc. launched Tinidazole 500, the first generic version of the FDA-approved drug Tindamax(R). Tindamax(R) is the only oral antimicrobial drug approved by the FDA for the treatment of both trichomoniasis (trich) and bacterial vaginosis (BV).
Epiduo(TM) Gel Combines Retinoid and Benzoyl Peroxide in a Single Product; Performs Better than Either Component Alone FORT WORTH, Texas, Jan. 6 /PRNewswire/ -- Galderma Laboratories, L.P.
According to Optimer Pharmaceuticals, its lead anti-infective drug candidate, OPT-80, showed higher clinical cure, global cure and recurrence rates in Phase III trials for the treatment of Clostridium difficile than the current standard of care, Vancocin.
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today released positive top-line results from a pivotal Phase 3 clinical study of the Company's lead anti-infective drug candidate, OPT-80, in patients with Clostridium difficile Infection (CDI).
By Chaudhry, Rama Joshy, Lovely; Kumar, Lalit; Dhawan, Benu Background & objectives: Frequent use of broad spectrum antibiotics in hospitalized patients has increased the incidence of Clostridium difficile diarrhoea in recent years. In our tertiary care hospital in north India, C.
LAUSANNE, Switzerland, July 16 /PRNewswire/ -- Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology, announced today that Japan's Ministry of Health, Labor and Welfare has approved Differin(R) Gel 0.1% (adapalene), a novel topical treatment for acne vulgaris in Japan.